A plant proteinase inhibitor from Crataeva tapia (CrataBL) attenuates elastase-induced pulmonary inflammatory, remodeling, and mechanical alterations in mice. Issue 11 (November 2015)

• Record Type: Journal Article
• Authors: Oliva, Leandro V.; Almeida-Reis, Rafael; Theodoro-Junior, Osmar; Oliveira, Bruno M.; Leick, Edna A.; Prado, Carla M.; Brito, Marlon V.; Correia, Maria Tereza dos Santos; Paiva, Patrícia M.G.; Martins, Mílton A.; Oliva, Maria Luiza V.; Tibério, Iolanda F.L.C.
• Is Part Of: Process biochemistry. Volume 50:Issue 11(2015:Nov.)
• Page Start: 1958
• Page End: 1965
• Publication Date: 2015-11
• Subjects: Elastase -- COPD -- CrataBL -- Proteinase inhibitor -- Pulmonary emphysema -- Pulmonary parenchyma; Biochemical engineering -- Periodicals; Biotechnology -- Periodicals; Biochemistry -- periodicals; Biotechnology -- periodicals; Chemical Engineering -- periodicals; Génie biochimique -- Périodiques; Biotechnologie -- Périodiques; Biochemical engineering; Biotechnology; Periodicals; 660.63
• DOI: 10.1016/j.procbio.2015.06.004
• Languages: English
• ISSNs: 1359-5113

Abstract

Graphical abstract: Highlights: CrataBL, a natural compound, attenuates elastase-induced pulmonary inflammation. CrataBL reduces oxidative stress responses induced by elastase. CrataBL decreases lung emphysema in mice. Potential therapeutic tool of CrataBL for COPD. Abstract: Chronic obstructive pulmonary disease (COPD) can lead to chronic and obstructive bronchitis and emphysema resulting in decreased bronchial lumen size. This study evaluated the effect of CrataBL, a protein isolated from the bark of Crataeva tapia, on lung mechanics, inflammation, and remodeling after elastase-induced pulmonary alterations in mice. The use of CrataBL led to decreased mechanical alterations, alveolar septum disruption (Lm), number of macrophage and neutrophil cells in the BALF, and TNF-α, MMP-9, MMP-12, TIMP-1, eNOS, and iNOS positive cells in the airways and alveolar walls compared to the animals in the ELA group. Moreover, a reduction in MUC-5-positive cells in the airway walls was observed. In conclusion, CrataBL attenuates changes in lung mechanics, inflammation, extracellular lung remodeling, and oxidative stress responses induced by the administration of elastase and decreased the volume fraction of isoprostane, collagen, and elastic fibers in the airways and alveolar walls compared to the animals in the ELA groups. Therefore, CrataBL is a potential therapeutic tool in the treatment of COPD.